NeoCell Therapeutics

📍 São Paulo, Brazil🗓 Founded 2025👥 2 employees
Health and Human Services
LinkedIn
NeoCell Therapeutics is developing breakthrough 3D biomimetic technology to produce high-quality blood stem cells in vitro for cancer therapy. Our proprietary platform mimics the native bone marrow microenvironment, enabling scalable stem cell expansion while preserving regenerative potential - solving a critical bottleneck in the field. With blood cancer incidence rising 3-5% annually and only 30% of patients finding optimal donors, NeoCells technology delivers immediate availability, higher compatibility, and reduced toxicity compared to current treatment options. Our platform eliminates the 3-6 month donor search timeline, providing life-saving solutions when patients need them most. We are targeting umbilical cord blood banks seeking to enhance their therapeutic offerings and specialized cancer treatment centers requiring on-demand access to expanded stem cell populations. Our artificial bone marrow model maintains stem cell potency during long-term culture, addressing core commercialization challenges that competitors using small molecule approaches have struggled to overcome. NeoCell is advancing toward clinical proof-of-concept with plans to establish regulatory pathways and strategic partnerships across the Americas and Europe, positioning to transform blood stem cell therapy for cancer patients worldwide. Revolutionizing cancer treatment through innovative stem cell technology.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2025
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was NeoCell Therapeutics founded?
NeoCell Therapeutics was founded in 2025.
What industry is NeoCell Therapeutics in?
NeoCell Therapeutics operates in Health and Human Services. Find similar Health and Human Services investors on gritt.io.
Where is NeoCell Therapeutics based?
NeoCell Therapeutics is headquartered in São Paulo, Brazil.